Skip to main content
. Author manuscript; available in PMC: 2016 Nov 1.
Published in final edited form as: Cancer Chemother Pharmacol. 2015 Sep 11;76(5):897–907. doi: 10.1007/s00280-015-2868-7

Figure 3.

Figure 3

Microtubule morphologic changes in PBMC's and tumor from a patient receiving E7389. Peripheral blood mononuclear cells (PBMC's) and serial tumor biopsy specimens were collected from pt #12 (metastatic NSCLC) prior to dose 1 of cycle 1, and then again 1 and 24 hours post-E7389 infusion. Cytospins were made from the PBMC's and 0.2 micron slides were cut from the tumor blocks and de-paraffinized prior to labeling. Slides were dual labeled for beta-tubulin (green) and DNA (red) and imaged by laser scanning fluorescence microscopy. The plasma E7389 concentrations measured at the corresponding collection times of the PBMC and tumor specimens are indicated on the left.